BK Virus Nephropathy and Kidney Transplantation | Zendy

Daniel L. Bohl | Zendy; Daniel C. Brennan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

BK Virus Nephropathy and Kidney Transplantation

Author(s) -

Daniel L. Bohl,

Daniel C. Brennan

Publication year - 2007

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.00920207

Subject(s) - medicine , bk virus , immunosuppression , cidofovir , nephropathy , leflunomide , kidney transplantation , transplantation , polyomavirus infections , chronic allograft nephropathy , immunology , kidney , kidney disease , urology , virus , endocrinology , methotrexate , diabetes mellitus

Nephropathy from BK virus (BKV) infection is an evolving challenge in kidney transplant recipients. It is the consequence of modern potent immunosuppression aimed at reducing acute rejection and improving allograft survival. Untreated BKV infections lead to kidney allograft dysfunction or loss. Decreased immunosuppression is the principle treatment but predisposes to acute and chronic rejection. Screening protocols for early detection and prevention of symptomatic BKV nephropathy have improved outcomes. Although no approved antiviral drug is available, leflunomide, cidofovir, quinolones, and intravenous Ig have been used. Retransplantation after BKV nephropathy has been successful.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research